高盛：予诺诚健华-B(09969)“买入”评级目标价升至21港元

智通财经2021-03-30

智通财经APP获悉，高盛发布研究报告，予诺诚健华-B(09969)“买入”评级，目标价升至21港元。报告中称，公司去年下半年取得亏损5700万元人民币，主要来自研发费用同比增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行表示，公司在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2123260880?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf","is_english":false,"pubTime":"2021-03-30 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2123260880","market":"hk","top_or_hot":-1,"title":"高盛：予诺诚健华-B(09969)“买入”评级 目标价升至21港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，高盛发布研究报告，予诺诚健华-B(09969)“买入”评级，目标价升至21港元。报告中称，公司去年下半年取得亏损5700万元人民币，主要来自研发费用同比增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行表示，公司在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/438372.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛：予诺诚健华-B(09969)“买入”评级 目标价升至21港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛：予诺诚健华-B(09969)“买入”评级 目标价升至21港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 14:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/438372.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，高盛发布研究报告，予诺诚健华-B(09969)“买入”评级，目标价升至21港元。报告中称，公司去年下半年取得亏损5700万元人民币，主要来自研发费用同比增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行表示，公司在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/438372.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"诺诚健华","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/438372.html","article_id":"2123260880","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/8e87285f5f61644eaba65898e6ccf2bf"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2123260880","pubTimestamp":1617087130,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，高盛发布研究报告，予诺诚健华-B“买入”评级，目标价升至21港元。该行表示，公司在研的BTK抑制剂奥布替尼今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，该行认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一，参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价，认为对BTK抑制剂市场价格有支持作用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"09969":"诺诚健华"},"translate_title":"Goldman Sachs: Yu Nuocheng Jianhua-B (09969) \"Buy\" rating target price rose to HK $21","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"90009":1,"09969":1},"content_text":"智通财经APP获悉，高盛发布研究报告，予诺诚健华-B(09969)“买入”评级，目标价升至21港元。报告中称，公司去年下半年取得亏损5700万元人民币，主要来自研发费用同比增长45%及营销及一般行政费用增长104%，但亏损已较2019年同期的2.43亿元人民币大幅减少。该行表示，公司在研的BTK抑制剂奥布替尼(Orelabrutinib)今年首季商业化进度理想，正计划将销售团队扩充至200人，今年内覆盖内地900家医院。另外，该行认为今年下半年潜在的国家医保药品目录谈判或为诺诚健华今年的增长动力之一，参考市场上其他BTK抑制剂Brukinsa及Imbruvica定价，认为对BTK抑制剂市场价格有支持作用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2123260880"}

高盛：予诺诚健华-B(09969)“买入”评级 目标价升至21港元

精彩评论

高盛：予诺诚健华-B(09969)“买入”评级目标价升至21港元